Patents by Inventor Sammy R. Shaver
Sammy R. Shaver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7749980Abstract: The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain, such as traumatic pain, neuropathic pain, organ pain and/or pain associated with diseases. The P2X receptor antagonists useful for this invention are non-nucleotide compounds of general Formula I. Compounds of Formula I can be used alone to treat pain. Compounds of Formula I can also be used in conjunction with other therapeutic agents or adjunctive therapies commonly used to treat pain, thus enhancing the therapeutic effect of pain reduction.Type: GrantFiled: October 21, 2004Date of Patent: July 6, 2010Assignee: Inspire Pharmaceuticals, Inc.Inventors: Robert Plourde, Jr., Sammy R. Shaver, Melwyn Anthony Abreo, Lorenzo Josue Alfaro-Lopez, Yangbo Feng, Tatyana V. Khasanova, Mark W. Holladay, Christopher S. Crean
-
Publication number: 20100160250Abstract: This invention provides a method for inhibiting the release of interleukin-1? in a mammal. This invention also provides a method for preventing or treating pulmonary diseases, ophthalmic diseases, and autoimmune diseases that are associated with inflammation or inflammatory conditions. The invention also provides a method for preventing or treating neurodegenerative diseases, or pain in a mammal. The method comprises administering to a mammal in need thereof a therapeutically effective amount of a mononucleoside compound, which is an antagonist of P2X7 receptor.Type: ApplicationFiled: December 17, 2009Publication date: June 24, 2010Inventors: James G. Douglass, III, Sammy R. Shaver, Tomas Navratil, José L. Boyer, Carl A. Samuelson, Jonathan B. DeCamp
-
Patent number: 7618949Abstract: The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.Type: GrantFiled: July 30, 2008Date of Patent: November 17, 2009Assignees: Inspire Pharmaceuticals, Inc., University of North Carolina at Chapel HillInventors: José L. Boyer, James G. Douglass, III, Sammy R. Shaver
-
Patent number: 7612047Abstract: The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.Type: GrantFiled: September 10, 2008Date of Patent: November 3, 2009Assignee: Inspire Pharmaceuticals, Inc.Inventors: James G. Douglass, III, Benjamin R. Yerxa, Sammy R. Shaver, Ward M. Peterson, Edward G. Brown, Christopher S. Crean, José L. Boyer
-
Patent number: 7592445Abstract: This invention is directed to compounds of Formulae III and V, useful for treating diseases or conditions associated with platelet aggregation.Type: GrantFiled: January 4, 2008Date of Patent: September 22, 2009Assignee: Inspire Pharmaceuticals, Inc.Inventors: Robert Plourde, Jr., Sammy R. Shaver, James G. Douglass, III, Paul S. Watson, José L. Boyer, Chi Tu, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova
-
Publication number: 20090076256Abstract: The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.Type: ApplicationFiled: September 10, 2008Publication date: March 19, 2009Inventors: James G. Douglass, III, Benjamin R. Yerxa, Sammy R. Shaver, Ward M. Peterson, Edward G. Brown, Christopher S. Crean, Jose L. Boyer
-
Publication number: 20080287671Abstract: The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.Type: ApplicationFiled: July 30, 2008Publication date: November 20, 2008Inventors: Jose L. Boyer, James G. Douglass, III, Sammy R. Shaver
-
Patent number: 7452870Abstract: The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.Type: GrantFiled: November 4, 2005Date of Patent: November 18, 2008Assignee: Inspire Pharmaceuticals, Inc.Inventors: José L. Boyer, James G. Douglass, III, Sammy R. Shaver
-
Patent number: 7435724Abstract: The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.Type: GrantFiled: November 21, 2005Date of Patent: October 14, 2008Assignee: Inspire Pharmaceutical, Inc.Inventors: James G. Douglass, III, Benjamin R. Yerxa, Sammy R. Shaver, Ward M. Peterson, Edward G. Brown, Christopher S. Crean, José L. Boyer
-
Patent number: 7368438Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formula I and III-XI, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds according to Formula I and III-XI.Type: GrantFiled: October 21, 2004Date of Patent: May 6, 2008Assignee: Inspire Pharmaceuticals, Inc.Inventors: Robert Plourde, Jr., Sammy R. Shaver, José L. Boyer, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova, Chi Tu
-
Patent number: 7335648Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.Type: GrantFiled: May 5, 2005Date of Patent: February 26, 2008Assignee: Inspire Pharmaceuticals, Inc.Inventors: Robert Plourde, Jr., Sammy R. Shaver, James G. Douglass, III, Paul S. Watson, José L. Boyer, Chi Tu, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova
-
Publication number: 20070249556Abstract: This invention provides methods of preventing and/or treating diseases or conditions associated with inflammation in a mammal, particularly a human. The method comprises administering to a mammal in need thereof an effective amount of a compound of Formula I, IA, or IB, wherein said amount is effective to inhibit inflammation. The invention also provides methods for inhibiting chemotaxis of leukocytes.Type: ApplicationFiled: April 19, 2007Publication date: October 25, 2007Inventors: Kurt E. Brubaker, Sammy R. Shaver, James G. Douglass
-
Patent number: 7132408Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y12 receptor antagonist compound, wherein said amount is effective to bind the P2Y12 receptors on platelets and inhibit ADP-induced platelet aggregation. The P2Y12 receptor antagonist compounds useful for this invention include mononucleoside 5?-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates of general Formula I, or salts thereof. The present invention also provides novel compounds of mononucleoside 5?-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates. The present invention further provides pharmaceutical formulations comprising mononucleoside 5?-monophosphates, mononucleoside polyphosphates, or dinucleoside polyphosphates.Type: GrantFiled: March 30, 2004Date of Patent: November 7, 2006Assignees: Inspire Pharmaceuticals, Inc., University of North CarolinaInventors: José L. Boyer, James G. Douglass, III, Sammy R. Shaver, Krzysztof Bednarski, Benjamin R. Yerxa, Gillian M. Olins
-
Publication number: 20040220133Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y12 receptor antagonist compound, wherein said amount is effective to bind the P2Y12 receptors on platelets and inhibit ADP-induced platelet aggregation. The P2Y12 receptor antagonist compounds useful for this invention include mononucleoside 5′-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates of general Formula I, or salts thereof. The present invention also provides novel compounds of mononucleoside 5′-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates. The present invention further provides pharmaceutical formulations comprising mononucleoside 5′-monophosphates, mononucleoside polyphosphates, or dinucleoside polyphosphates.Type: ApplicationFiled: March 31, 2004Publication date: November 4, 2004Inventors: Jose L. Boyer, James G. Douglass, Sammy R. Shaver, Krzysztof Bednarski, Benjamin R. Yerxa, Gillian M. Olins
-
Patent number: 6462028Abstract: The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Y2 and/or P2Y4 purinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and various disease states as well as the treatment of vulvar pain is discussed. Suitable agonists such as UTP, CTP, ATP, dinucleotides and analogs thereof are disclosed.Type: GrantFiled: November 25, 1998Date of Patent: October 8, 2002Assignee: Inspire Pharmaceuticals, Inc.Inventors: William Pendergast, Sammy R. Shaver, David J. Drutz, Janet L. Rideout, Benjamin R. Yerxa
-
Publication number: 20020052336Abstract: The invention provides a method of regulating water and mucin secretions and fluid transport in the gastrointestinal tract. The invention also provides a method for treating a gastrointestinal disease in which the mucosal barrier of the gastrointestinal system is impaired. The invention additionally provides a method for correcting disorders of fluid secretion or absorption in the gastrointestinal system. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor agonist, in an amount effective to regulate water and mucin secretions or to correct abnormal fluid transport in the gastrointestinal tract.Type: ApplicationFiled: December 22, 2000Publication date: May 2, 2002Inventors: Benjamin R. Yerxa, Janet L. Rideout, William Pendergast, Sammy R. Shaver, Zhen Zhang, Ward M. Peterson, Matthew Cowlen
-
Publication number: 20020013289Abstract: The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Y2 and/or P2Y4 purinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and various disease states as well as the treatment of vulvar pain is discussed. Suitable agonists such as UTP, CTP, ATP, dinucleotides and analogs thereof are disclosed.Type: ApplicationFiled: November 25, 1998Publication date: January 31, 2002Inventors: WILLIAM PENDERGAST, SAMMY R. SHAVER, DAVID J. DRUTZ, JANET L. RIDEOUT
-
Patent number: 5064946Abstract: Several novel 3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranosyl derivatives of substituted pyrimidinones having antiretroviral, especially anti-AIDS, activity are described.Type: GrantFiled: December 20, 1989Date of Patent: November 12, 1991Assignee: Burroughs Wellcome Co.Inventors: Sammy R. Shaver, George A. Freeman, Janet L. Rideout
-
Patent number: 5041543Abstract: A compound 1-(3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranoxyl)-5-methyl-2(1H)-pyr imidinone and its use in a method of generating (forming, providing) 3'-azido-3'-deoxythymidine (zidovudine sometimes referred to as AZT) in the body of an animal (a mammal such as human) by systemically administering 1-(3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranosyl)-5-methyl-2(1H)-pyr iminone to said animal (mammal such as a human) is disclosed. AZT is approved and used for treating HIV infections, e.g., AIDS and ARC in humans and also has activity against gram-negative bacteria in animals.Type: GrantFiled: September 16, 1988Date of Patent: August 20, 1991Assignee: Burroughs Wellcome Co.Inventors: Sammy R. Shaver, George A. Freeman, Janet L. Rideout